Evidence map›Paper›PMID 33428936›Full record

ArticleThe Journal of biological chemistry

Proteomic identification and validation of novel interactions of the putative tumor suppressor PRELP with membrane proteins including IGFI-R and p75NTR.

Hirofumi Kosuge, Makoto Nakakido, Satoru Nagatoishi, Tetsuya Fukuda, Yasuhiko Bando, Shin-Ichi Ohnuma, Kouhei Tsumoto

Abstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Tumor Suppressive Role of theJournal of personalized medicine · 2022
    Article
  12. Article
  13. Article
  14. Cancers · 2022
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hirofumi KosugeSchool of Engineering, The University of Tokyo, Tokyo, Japan.
Makoto NakakidoSchool of Engineering, The University of Tokyo, Tokyo, Japan.
Satoru NagatoishiThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tetsuya FukudaBiosys Technologies, Tokyo, Japan.
Yasuhiko BandoBiosys Technologies, Tokyo, Japan.
Shin-Ichi OhnumaThe Institute of Ophthalmology, University College London, London, United Kingdom.
Kouhei TsumotoSchool of Engineering, The University of Tokyo, Tokyo, Japan; The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: tsumoto@bioeng.t.u-tokyo.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proline and arginine-rich end leucine-rich repeat protein (PRELP) is a member of the small leucine-rich repeat proteoglycans (SLRPs) family. Levels of PRELP mRNA are downregulated in many types of cancer, and PRELP has been reported to have suppressive effects on tumor cell growth, although the molecular mechanism has yet to be fully elucidated. Given that other SLRPs regulate signaling pathways through interactions with various membrane proteins, we reasoned that PRELP likely interacts with membrane proteins to maintain cellular homeostasis. To identify membrane proteins that interact with PRELP, we carried out coimmunoprecipitation coupled with mass spectrometry (CoIP-MS). We prepared membrane fractions from Expi293 cells transfected to overexpress FLAG-tagged PRELP or control cells and analyzed samples precipitated with anti-FLAG antibody by mass spectrometry. Comparison of membrane proteins in each sample identified several that seem to interact with PRELP; among them, we noted two growth factor receptors, insulin-like growth factor I receptor (IGFI-R) and low-affinity nerve growth factor receptor (p75NTR), interactions with which might help to explain PRELP's links to cancer. We demonstrated that PRELP directly binds to extracellular domains of these two growth factor receptors with low micromolar affinities by surface plasmon resonance analysis using recombinant proteins. Furthermore, cell-based analysis using recombinant PRELP protein showed that PRELP suppressed cell growth and affected cell morphology of A549 lung carcinoma cells, also at micromolar concentration. These results suggest that PRELP regulates cellular functions through interactions with IGFI-R and p75NTR and provide a broader set of candidate partners for further exploration.

Indexed as

A549 CellsCarcinoma, Non-Small-Cell LungExtracellular Matrix ProteinsGene Expression Regulation, NeoplasticGlycoproteinsHumansNerve Tissue ProteinsProteomicsReceptors, Nerve Growth FactorRecombinant ProteinsRNA, MessengerExtracellular Matrix ProteinsGlycoproteinsNerve Tissue ProteinsNGFR protein, humanPRELP protein, humanReceptors, Nerve Growth FactorRecombinant ProteinsRNA, Messengercoimmunoprecipitationgrowth factor receptormembrane proteinPRELPprotein–protein interactionproteomicssmall leucine-rich proteoglycan (SLRP)surface plasmon resonance (SPR)

Identifiers

PMID33428936
PMCPMC7948961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.